Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) Study
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 184 participants.
Also called NCT04327232
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 184 participants
- Registry
-
NCT04327232
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Singapore
- Registry status
- Unknown status
Technical summary
Registry record NCT04327232. Randomized; triple masking; primary purpose prevention. Start 2018-05-23 (actual); primary completion 2022-05-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) Study
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Spironolactone 25mg
- Intervention (Drug)
- Placebo oral tablet
- Lead sponsor
- National University Hospital, Singapore
- Collaborator
- University of Otago
Record details
- Record id
cardio:ct-nct04327232- Content hash
943499e807feb2ea8c805271e42a022ed7c729c9b8b959044154fab4e4317e34